Physician profile
Robert Lowe
NPI 1053360693
$26,144.47
in general payments reported to CMS, 2019-2025
20 companies · $5,038 in 2025
The $5,038 reported for 2025 was more than what 89% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $826 · 2021: $3,478 · 2022: $2,882 · 2023: $7,804 · 2024: $4,982 · 2025: $5,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,697.50 |
| Food and Beverage | $6,125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18,054.59 | 2019-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $1,480.55 | 2019-2025 | |
| Amgen INC. | $1,399.03 | 2019-2025 | Otezla, Enbrel, Avsola |
| E.R. Squibb & Sons, L.L.C. | $1,308.14 | 2019-2024 | Orencia |
| Astrazeneca Pharmaceuticals LP | $1,110.00 | 2024 | |
| Abbvie INC. | $981.99 | 2019-2025 | |
| Organon LLC | $251.91 | 2021-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $238.96 | 2024-2025 | Benlysta |
| Pfizer INC. | $195.74 | 2021-2025 | |
| Sobi, INC | $175.80 | 2019-2025 | |
| Octapharma USA, INC. | $175.05 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Antares Pharma, INC. | $165.90 | 2020-2021 | |
| Kyowa Kirin, INC. | $165.43 | 2023-2025 | Crysvita |
| Janssen Biotech, INC. | $156.14 | 2022-2025 | Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $95.18 | 2023-2025 | Hyqvia, Cuvitru |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $58.23 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $47.47 | 2023-2025 | Idacio |
| Ucb, INC. | $40.40 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2024 | Cyltezo |
| Genentech USA, INC. | $21.83 | 2023 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.